Observational studyThe Ulster medical journal2026
Thrombosis and Survival after Prothrombin Complex Concentrate Use to treat Oral Anticoagulant Associated Haemorrhage.
Observational study in The Ulster medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent trials for treatments of direct oral anticoagulant (DOAC) related acute haemorrhage have highlighted incidences of post treatment thrombosis. Prothrombin complex concentrate (PCC) is widely used for reversal of anticoagulant associated bleeding, yet thrombotic risks following PCC administration, particularly for DOACs, remain incompletely characterised in real-world settings. Methods: This retrospective observational study analysed thrombotic and survival outcomes in 682 patients that received PCC for OAC associated haemorrhage in the Belfast Health and Social Care Trust between 2015-2021. Patients were categorised by OAC type (warfarin, rivaroxaban, apixaban and edoxaban). Primary outcome was thrombotic event rate at 30 days, while secondary outcomes included 30- and 90day mortality and anticoagulation resumption rates. Results: The cohort comprised 393 warfarin patients, 55 rivaroxaban, 221 apixaban and 13 edoxaban patients. Intracranial haemorrhage predominated (47-69% across DOAC groups vs. 49% warfarin). Thrombotic event rates were significantly higher in DOAC patients (rivaroxaban 13%, apixaban 8%, overall DOAC 8.7%) compared to warfarin (5%). Thirty-day mortality rates ranged from 13-23% across oral anticoagulant groups. Anticoagulation was resumed in only 29-47% of patients. Conclusions: The findings suggest that PCC may be as effective as specific antidotes for DOAC reversal. In the absence of universal access to specific reversal agents, PCC continues to serve an important role in managing life threatening anticoagulant associated haemorrhage. Systematic pathways for post reversal anticoagulation resumption should be implemented to optimise patient outcomes.
Indexed as
Identifiers
42327596PMC13278053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.